Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 113715 in drug-naïve type 2 diabetes
NCT00330330Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Feb 2003
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of IONIS-PTP-1BRx in type 2 diabetes mellitus (T2DM), sponsored by Ionis Pharmaceuticals. Primary endpoints: Safety and Tolerability, Pharmacokinetic Profile and 1 more. Started Feb 2003; status: completed.
02
Drugs
IONIS-PTP-1BRx
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00330330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00330330.